CIS Biotech, an Atlanta-based medical technology firm, will be participating in the November 15 to 19 MEDICA trade show in Düsseldorf, Germany, as part of the pavilion presence of the U.S. Department of Commerce.
Established in 2000, the mission of CIS Biotech, Inc. is to bring unique disease-associated biomarkers and in-vitro diagnostic (IVD) tools to the market, in order to solve unmet needs in risk assessment of stroke.
The firm is headed by Robert R. Rhinehart, CEO and Chairman of the Board; its Scientific Board of Consultants provides services under the leadership of Svetlana A. Dambinova, DSci., Ph.D.
“Our company is beginning to license the use of its proprietary, patented, diagnostic tools”, Mr. Rhinehart stated recently, “and MEDICA is therefore a good venue for us to interact with the medical diagnostics industry.” He cited a recent agreement with Bayer HealthCare, Diagnostics Division, a member of the Bayer Group, as an example of companies that have already expressed an interest in partnerships with CIS Biotech.
CIS Biotech will be represented in Düsseldorf by CEO/Chairman Robert Rhinehart.